Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC15231 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 375 |
0.1-0.2 | 20080 |
0.2-0.3 | 9061 |
0.3-0.4 | 1099 |
0.4-0.5 | 213 |
0.5-0.6 | 46 |
0.6-0.7 | 11 |
0.7-0.8 | 3 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 1 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC15231 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 116 |
0.1-0.2 | 4825 |
0.2-0.3 | 3404 |
0.3-0.4 | 637 |
0.4-0.5 | 119 |
0.5-0.6 | 33 |
0.6-0.7 | 20 |
0.7-0.8 | 7 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.7907 |
Intermediate Similarity |
NPD718 |
Approved |
0.7907 |
Intermediate Similarity |
NPD390 |
Approved |
0.7805 |
Intermediate Similarity |
NPD2707 |
Clinical (unspecified phase) |
0.7551 |
Intermediate Similarity |
NPD3721 |
Approved |
0.7551 |
Intermediate Similarity |
NPD3722 |
Approved |
0.7179 |
Intermediate Similarity |
NPD5385 |
Approved |
0.7179 |
Intermediate Similarity |
NPD5384 |
Approved |
0.6923 |
Remote Similarity |
NPD3734 |
Approved |
0.6923 |
Remote Similarity |
NPD2705 |
Approved |
0.6923 |
Remote Similarity |
NPD2706 |
Approved |
0.675 |
Remote Similarity |
NPD2274 |
Approved |
0.675 |
Remote Similarity |
NPD2275 |
Approved |
0.6667 |
Remote Similarity |
NPD2273 |
Clinical (unspecified phase) |
0.6471 |
Remote Similarity |
NPD4834 |
Discontinued |
0.6415 |
Remote Similarity |
NPD4839 |
Approved |
0.64 |
Remote Similarity |
NPD5379 |
Clinical (unspecified phase) |
0.6341 |
Remote Similarity |
NPD1156 |
Clinical (unspecified phase) |
0.62 |
Remote Similarity |
NPD874 |
Approved |
0.62 |
Remote Similarity |
NPD872 |
Approved |
0.619 |
Remote Similarity |
NPD2276 |
Clinical (unspecified phase) |
0.6098 |
Remote Similarity |
NPD401 |
Approved |
0.6071 |
Remote Similarity |
NPD627 |
Approved |
0.6071 |
Remote Similarity |
NPD625 |
Approved |
0.6071 |
Remote Similarity |
NPD628 |
Phase 3 |
0.6071 |
Remote Similarity |
NPD626 |
Phase 3 |
0.6038 |
Remote Similarity |
NPD5793 |
Discontinued |
0.6 |
Remote Similarity |
NPD3727 |
Discontinued |
0.5758 |
Remote Similarity |
NPD5365 |
Phase 2 |
0.5714
|
Remote Similarity |
NPD9458 |
Approved |